Skip to main content

Gilman Steven C

No open-market purchases or sales filed in the past year.

Current role at each company

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought
–
0 filings
Sold
–
0 filings
Net
–
Bought minus sold
Companies
0
With open-market trades

Trades

Every Form 4 that lists Gilman Steven C as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

VCEL Vericel Corp

Director8 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Oct 18, 2024 (view filing)Oct 162 daysGilman Steven CDirectorSSale−5.83K$41.36−$241.3K−34.7%11.0K after10b5-1
Oct 4, 2024 (view filing)Oct 22 daysGilman Steven CDirectorSSale−5.83K$40.35−$235.4K−34.7%11.0K after10b5-1
Sep 20, 2024 (view filing)Sep 182 daysGilman Steven CDirectorSSale−5.83K$45.54−$265.7K−34.7%11.0K after10b5-1
Sep 5, 2024 (view filing)Sep 41 dayGilman Steven CDirectorSSale−5.00K$48.58−$242.9K−31.3%11.0K after10b5-1
May 2, 2022 (view filing)Apr 293 daysGilman Steven CDirectorSSale−900$30.94−$27.8K−14.8%5.20K after
Dec 1, 2021 (view filing)Nov 292 daysGilman Steven CDirectorSSale−5.00K$39.17−$195.8K−58.8%3.50K after
Oct 28, 2021 (view filing)Oct 271 dayGilman Steven CDirectorSSale−5.00K$50.57−$252.8K−58.8%3.50K after
Oct 1, 2021 (view filing)Sep 301 dayGilman Steven CDirectorSSale−5.00K$48.85−$244.3K−58.8%3.50K after

AKBA Akebia Therapeutics, Inc.

Director1 trade

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jun 7, 2022 (view filing)4:03 PM ETJun 34 daysGilman Steven CDirectorSSale−4.57K$0.362−$1.65K−9.5%43.4K after